{
    "clinical_study": {
        "@rank": "163035", 
        "arm_group": [
            {
                "arm_group_label": "Group A - Early Imaging", 
                "arm_group_type": "Active Comparator", 
                "description": "Group A will receive SPECT imaging 3 times during the study. The first scan will take place prior to the initiation of any treatment, followed by scans at week 26 and week 52."
            }, 
            {
                "arm_group_label": "Group B - Delayed Imaging", 
                "arm_group_type": "Active Comparator", 
                "description": "Group B will receive SPECT imaging 2 times during the study. Group B will not have the first scan (prior to the initiation of any treatment).  Scan will take place at week 26 and week 52."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the impact of imaging the brain as a diagnostic\n      tool in the management of early Parkinson's disease (PD)."
        }, 
        "brief_title": "Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "The imaging drug used in this study is Ioflupane (123I) Injection, also referred to as\n      DaTscan.  DaTscan is FDA approved."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18-80;\n\n          -  diagnosis of idiopathic PD exhibiting at least 2 of 3 cardinal signs (bradykinesia,\n             rigidity and resting tremor);\n\n          -  maximum duration of previous exposure to anti-parkinsonian therapy being < 8 weeks;\n\n          -  ability to signed informed consent;\n\n          -  willingness and ability to complete medication diary and questionnaires;\n\n          -  if a female subject of child-bearing potential, the use of an effective method of\n             contraception.\n\n        Exclusion Criteria:\n\n          -  current treatment with anti-parkinsonian medication;\n\n          -  previous treatment with anti-parkinsonian medication for greater than 8 weeks;\n\n          -  inability to complete questionnaires;\n\n          -  unwillingness to complete all questionnaires and medication diary;\n\n          -  subjects with secondary causes of parkinsonism;\n\n          -  participant has evidence of clinical significant thyroid disease, gastrointestinal,\n             cardiovascular, hepatic, renal, hematologic, neoplastic, endocrine, neurologic,\n             immunodeficiency, pulmonary, or other medical or psychiatric disorder;\n\n          -  positive serum/urine pregnancy test at any time during the study period;\n\n          -  the participant has a history of alcohol, narcotic, or any other drug abuse as\n             defined by the DSM-IV within the past 2 years;\n\n          -  participation in a concurrent PD trial within 60 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788696", 
            "org_study_id": "Pro00036503"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A - Early Imaging", 
                "description": "Total of 3 scans", 
                "intervention_name": "Group A - Early Imaging", 
                "intervention_type": "Radiation", 
                "other_name": "[123I]-FP-CIT SPECT"
            }, 
            {
                "arm_group_label": "Group B - Delayed Imaging", 
                "description": "Total of 2 scans", 
                "intervention_name": "Group B - Delayed Imaging", 
                "intervention_type": "Radiation", 
                "other_name": "[123I]-FP-CIT SPECT"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Parkinsonism", 
            "Idiopathic Parkinson Disease"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27705"
                }, 
                "name": "Duke University Health Center"
            }, 
            "investigator": {
                "last_name": "Patrick Hickey, DO", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection)", 
        "overall_contact": {
            "email": "jessica.carlson@duke.edu", 
            "last_name": "Jessica Carlson", 
            "phone": "919-668-2841"
        }, 
        "overall_official": {
            "affiliation": "Duke University Health Center", 
            "last_name": "Patrick Hickey, DO", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patient and treating physician agree on a treatment plan at visit 3.  Patient adherence to medications will be evaluated based on pill count at each follow-up study visit.  Additionally, each patient will record their adherence to therapy on the Patient Expectations and Disease-related Questionnaire (PEDQ) at each follow-up study visit, allowing the study team to track compliance with pharmacologic therapy as well as treatments including therapy exercise plans.", 
            "measure": "Patient adherence to treatment plan", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788696"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Other outcome measures will be between any group differences in UPDRS.", 
                "measure": "Unified Parkinson Disease Rating Scale (UPDRS)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Other outcome measures will be between any group differences in LOT-R.  This test assesses individual differences in generalized optimism versus pessimism.", 
                "measure": "Life Orientation Test - Revised (LOT-R)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Other outcome measures will be between any group differences in MCSD.  This test assesses the extent to which individuals attempt to depict themselves as similar to the norms and standards of their society and community.", 
                "measure": "Marlowe - Crowne Social Desirability Scale (MCSD)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Other outcome measures will be between any group differences in OCI.  This self-report scale assesses distress from symptoms commonly experienced in obsessive-compulsive disorder.", 
                "measure": "Obsessive - Compulsive Inventory (OCI)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Other outcome measures will be between any group differences in EGCR.", 
                "measure": "Expectation of Global Response (EGCR)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "GE Healthcare", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}